Clinical, biochemical, and genetic spectrum of MADD in a South African cohort: an ICGNMD study
Michelle Bisschoff,Izelle Smuts,Marli Dercksen,Maryke Schoonen,Barend C. Vorster,George van der Watt,Careni Spencer,Kireshnee Naidu,Franclo Henning,Surita Meldau,Robert McFarland,Robert W. Taylor,Krutik Patel,Mahmoud R. Fassad,Jana Vandrovcova,Ronald J. A. Wanders,Francois H. van der Westhuizen,The ICGNMD Consortium
DOI: https://doi.org/10.1186/s13023-023-03014-8
2024-01-17
Orphanet Journal of Rare Diseases
Abstract:Multiple acyl-CoA dehydrogenase deficiency (MADD) is an autosomal recessive disorder resulting from pathogenic variants in three distinct genes, with most of the variants occurring in the electron transfer flavoprotein-ubiquinone oxidoreductase gene ( ETFDH) . Recent evidence of potential founder variants for MADD in the South African (SA) population, initiated this extensive investigation. As part of the International Centre for Genomic Medicine in Neuromuscular Diseases study, we recruited a cohort of patients diagnosed with MADD from academic medical centres across SA over a three-year period. The aim was to extensively profile the clinical, biochemical, and genomic characteristics of MADD in this understudied population.
genetics & heredity,medicine, research & experimental